Medical Communications

Showing 15 posts of 6402 posts found.

Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality

January 25, 2024 Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab

Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …

UKHSA warns of measles outbreak

January 22, 2024 Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination

The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …

FDA approves Balversa for bladder cancer treatment

January 22, 2024 Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
anirudh-djo3injpaoe-unsplash_3

AstraZeneca’s Voydeya approved in Japan for PNH treatment

January 19, 2024 Medical Communications AstraZeneca, Haematology, PNH, Voydeya

AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

January 19, 2024 Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …

FDA clears DermaSensor’s AI detection device for skin cancer

January 18, 2024 Medical Communications FDA, Oncology, skin cancer

DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …

Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment

January 18, 2024 Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial

Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

January 15, 2024 Medical Communications FDA, Oncology, cervical cancer, keytruda

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024 Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024 Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024 Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement

January 5, 2024 Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial

Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …

Renovos Biologics gains FDA Breakthrough Device Designation for Renovite

January 4, 2024 Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation

Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …

Calliditas Therapeutics gains FDA approval of Tarpeyo

December 22, 2023 Medical Communications Calliditas, FDA, Nephrology, kidneys

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …

FDA approves AstraZeneca and Ionis’s Wainua

December 22, 2023 Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua

AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …
The Gateway to Local Adoption Series

Latest content